Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Secondary Arthritis Clear all
Completed Phase 4 Interventional Results available

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

NCT01147341
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Placebo
Drug
Lead sponsor
Michael Schiff, MD
Individual
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

NCT03311854
View directory record Official record
Conditions
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
0 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

NCT00195663
View directory record Official record
Conditions
Early Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Jul 23, 2026, 10:45 PM EDT
Suspended No phase listed Observational

Serum and Synovium Protease Inhibitor Levels in Primary and Secondary Osteoarthritic Joints

NCT01613833
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Blood Draw, Joint Aspirate Harvest
Procedure
Lead sponsor
Scuderi, Gaetano J., M.D.
Other
Eligibility
19 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Jul 23, 2026, 10:45 PM EDT
Terminated No phase listed Observational

3DKnee™ System vs. the MJS Knee System

NCT00764803
View directory record Official record
Conditions
Rheumatoid Arthritis, Traumatic Arthritis, Joint Disease Secondary to Osteoarthritis
Interventions
Encore 3DKnee™ system, Encore MJS™ Knee System
Device
Lead sponsor
Encore Medical, L.P.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Jul 23, 2026, 10:45 PM EDT
Active, not recruiting Not applicable Interventional

Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System

NCT04770870
View directory record Official record
Conditions
Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
Interventions
Hintermann Series H3 Total Ankle Replacement System
Device
Lead sponsor
DT MedTech, LLC
Industry
Eligibility
21 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Little Rock, Arkansas • Mission Hills, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Terminated No phase listed Observational

Foundation Knee Study - Retrospective

NCT00764894
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic Arthritis, Inflammatory Tissue Disorders, Arthritis Secondary to Other Diseases, Avascular Necrosis of the Femoral Condyles
Interventions
Foundation Knee
Device
Lead sponsor
Encore Medical, L.P.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Vero Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2011 · Synced Jul 23, 2026, 10:45 PM EDT
Recruiting No phase listed Observational

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

NCT06339177
View directory record Official record
Conditions
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 2Phase 3 Interventional

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

NCT00035334
View directory record Official record
Conditions
Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome, Kidney Diseases, Gastrointestinal Diseases
Interventions
NC-503 (Anti-amyloidotic (AA) Agent)
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2006 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

NCT05001737
View directory record Official record
Conditions
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
6 Months to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA)

NCT03362957
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Geniculate Artery Embolization, Sham Procedure
Device · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Woodbridge, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Mobile - Bearing Knee Study

NCT00765362
View directory record Official record
Conditions
Inflammatory Tissue Disorder, Osteoarthritis, Avascular Necrosis, Post-traumatic Arthritis, Secondary Arthritis
Interventions
Encore Mobile-Bearing Knee
Device
Lead sponsor
Encore Medical, L.P.
Industry
Eligibility
18 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
8
States / cities
Phoenix, Arizona • Fountain Valley, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Jul 23, 2026, 10:45 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401
View directory record Official record
Conditions
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
Interventions
AP01, Placebo
Drug · Other
Lead sponsor
Avalyn Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
61
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Withdrawn Phase 2 Interventional

Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study

NCT02027298
View directory record Official record
Conditions
Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis, Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jul 23, 2026, 10:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

NCT05754190
View directory record Official record
Conditions
Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions
SOMA pain manager smartphone application
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 23, 2026, 10:45 PM EDT
Recruiting Not applicable Interventional

Early Feasibility Study of Cartilage Defect Repair

NCT06823089
View directory record Official record
Conditions
Osteoarthritis, Hip, Femoroacetabular Impingement, Osteonecrosis, Legg-Calvé-Perthes Disease, Osteochondral Lesion, Hip Dysplasia
Interventions
ReNew Hip Implant
Device
Lead sponsor
Cytex Therapeutics, Inc.
Other
Eligibility
14 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Geniculate Artery Embolization for the Treatment of Knee Pain

NCT02850068
View directory record Official record
Conditions
Osteoarthritis Of Knee
Interventions
Geniculate Artery Embolization
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Woodbridge, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jul 23, 2026, 10:45 PM EDT
Withdrawn Early Phase 1 Interventional

Terbinafine Treatment of Axial Spondyloarthropathy

NCT05119712
View directory record Official record
Conditions
Ankylosing Spondylitis, Axial Spondyloarthritis, Psoriatic Spondylitis, Spondylitis Secondary to Inflammatory Bowel Disease, Axial Spondyloarthopathy
Interventions
Terbinafine Tablets, Laboratory Testing
Drug · Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Jul 23, 2026, 10:45 PM EDT
Recruiting Phase 3 Interventional

The Beat Pain Better Trial

NCT06932887
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain Management
Interventions
Text Messaging, Motivational Messaging, Physical Activity Counseling and Self-Directed Walk with Ease, Enhanced Walk with Ease
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
45 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Salt Lake City, Utah • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 23, 2026, 10:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multicenter Bone and Joint Health Study

NCT03033238
View directory record Official record
Conditions
Osteoarthritis,Knee
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 79 Years
Enrollment
4,185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Jul 23, 2026, 10:45 PM EDT